European Union - English - EMA (European Medicines Agency)

intervet international bv - live deletion-mutant streptococcus equi strain tw928 - immunologicals for equidae - horses - for immunisation of horses against streptococcus equi to reduce clinical signs and occurrence of lymph-node abscesses.onset of immunity: the onset of immunity is established as two weeks after basic vaccination.duration of immunity: the duration of immunity is up to three months.the vaccine is intended for use in horses for which a risk of streptococcus equi infection has been clearly identified, due to contact with horses from areas where this pathogen is known to be present, e.g. stables with horses that travel to shows or competitions in such areas, or stables that obtain or have livery horses from such areas.

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - streptococcus equi (live) - streptococcus equi (live) 750 g/litre - vaccine

European Union - English - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologicals for equidae - horses - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - streptococcus equi - lyophilisate for suspension for injection - live bacterial vaccine - horses

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - streptococcus pneumoniae serotype 7f capsular polysaccharide; streptococcus pneumoniae serotype 8 capsular polysaccharide; streptococcus pneumoniae serotype 9n capsular polysaccharide; streptococcus pneumoniae serotype 9v capsular polysaccharide; streptococcus pneumoniae serotype 10a capsular polysaccharide; streptococcus pneumoniae serotype 11a capsular polysaccharide; streptococcus pneumoniae serotype 12f capsular polysaccharide; streptococcus pneumoniae serotype 14 capsular polysaccharide; streptococcus pneumoniae serotype 15b capsular polysaccharide; streptococcus pneumoniae serotype 17a or 17f capsular polysaccharide; streptococcus pneumoniae serotype 18c capsular polysaccharide; streptococcus pneumoniae serotype 19f capsular polysaccharide; streptococcus pneumoniae serotype 19a capsular polysaccharide; streptococcus pneumoniae serotype 20 capsular polysaccharide; streptococcus pneumoniae serotype 22f capsular polysaccharide; streptococcus pneumoniae serotype 23f capsular polysaccharide; streptococcus pneumoniae serotype 33f capsular polysaccharide; streptococcus pneumoniae serotype 1 capsular polysaccharide; streptococcus pneumoniae serotype 2 capsular polysaccharide; streptococcus pneumoniae serotype 3 capsular polysaccharide; streptococcus pneumoniae serotype 4 capsular polysaccharide; streptococcus pneumoniae serotype 5 capsular polysaccharide; streptococcus pneumoniae serotype 6b capsular polysaccharide - solution for injection

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a - live ge- tk- double-gene-deleted bovine herpes virus type 1, strain ceddel: 106.3–107.3 ccid50 - immunologicals - cattle - for the active immunisation of cattle from three months of age against bovine herpes virus type 1 (bohv-1) to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.onset of immunity: 21 days after completion of the basic vaccination scheme.duration of immunity: 6 months after completion of the basic vaccination scheme

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - live newcastle disease virus clone 30 - lyophilisate for oculonasal suspension/use in drinking water - . - newcastle disease virus / paramyxovirus - chickens, turkeys - immunological - live vaccine

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - live aroa-gene deleted escherichia coli,type o78,ec34195 - unknown - live aroa-gene deleted escherichia coli,type o78,ec34195 vaccine-microbial active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.